Novo Nordisk will host an investor event covering ADA 2026 data and the Wegovy\u00ae pill commercial milestone on June 7, 2026 at 6:30 pm CDT. The event will be accessible via live webcast on the\u00a0Novo Nordisk investor website<\/a>.<\/p>\n
*Pay as little as $25, subject to a maximum savings of $100\/month. Eligibility and restrictions apply. Government beneficiaries excluded. Month defined as 1 box of 4 pens of Wegovy\u00ae and 1 bottle of 30 tablets of Wegovy\u00ae. Novo Nordisk reserves the right to modify or cancel this program at any time. See full terms at WegovyTerms.com and NovoCarePharmacyTerms.com.
\u2020Terms apply. For eligible Medicare patients prescribed Wegovy\u00ae\u00a0for a covered FDA-approved indication. Eligibility criteria will be determined by CMS. This information is not a guarantee of coverage. Month defined as 1 box of 4 pens of Wegovy\u00ae\u00a0and 1 bottle of 30 tablets of Wegovy\u00ae.<\/p>\n
About the prescription data
The source data for the over 3 million prescriptions for all strengths of Wegovy\u00ae pill includes Novo Nordisk Inc. partner-reported paid claims only from January 5, 2026 through June 2, 2026. Pharmaceutical launch volume data based on IQVIA paid total prescriptions (TRx) of over 1888 US branded launches analyzed (excluding vaccines) since 2013, at 4 months post launch. Source data for 82% of Wegovy\u00ae pill new-to-brand (NBRx) starts year-to-date (YTD) 2026 is IQVIA LRx, YTD based on week ending January 9, 2026 through May 15, 2026, with “new to GLP-1” based on 12 months look back for any other (obesity or diabetes) GLP-1 medicine (not including compounded products). IQVIA data of paid TRx and paid NBRx data were used to measure Wegovy\u00ae pill or Wegovy\u00ae HD volume data over the specified time periods, with NBRx using a 12\u00a0month\u00a0lookback period; if a paid prescription for the same brand does not\u00a0exist\u00a0in the look back period, then a script is\u00a0deemed\u00a0to be new to the brand.1<\/p>\n
What is Wegovy\u00ae?<\/p>\n
Wegovy\u00ae (semaglutide) tablets are a prescription medicine used with a reduced-calorie diet and increased physical activity to:<\/p>\n
reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.<\/p>\n
Wegovy\u00ae (semaglutide) injection is a prescription medicine used with a reduced-calorie diet and increased physical activity to:<\/p>\n
reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.<\/p>\n
Wegovy\u00ae contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.<\/p>\n
It is not known if Wegovy\u00ae injection is safe and effective:<\/p>\n
to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in people under 18 years<\/p>\n
to help children under 12 years of age lose weight and keep the weight off<\/p>\n
It is not known if Wegovy\u00ae tablets are safe and effective for use in people under 18 years of age.<\/p>\n
Important Safety Information<\/p>\n
What is the most important information I should know about Wegovy\u00ae?
Wegovy\u00ae may cause serious side effects, including:<\/p>\n
Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy\u00ae and other medicines that work like Wegovy\u00ae caused thyroid tumors, including thyroid cancer. It is not known if Wegovy\u00ae will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people<\/p>\n
Do not use Wegovy\u00ae if:<\/p>\n
you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)<\/p>\n
you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy\u00ae injection or Wegovy\u00ae tablets. See symptoms of serious allergic reaction in\u00a0“What are the possible side effects of Wegovy\u00ae?”<\/p>\n
Before using Wegovy\u00ae, tell your healthcare provider if you have any other medical conditions, including if you:<\/p>\n
have or have had problems with your pancreas or kidneys<\/p>\n
have type 2 diabetes and a history of diabetic retinopathy<\/p>\n
are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)<\/p>\n
are pregnant or plan to become pregnant. Wegovy\u00ae may harm your unborn baby. You should stop using Wegovy\u00ae 2 months before you plan to become pregnant<\/p>\n
are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with Wegovy\u00ae tablets. It is not known if Wegovy\u00ae when received through an injection passes into your breast milk<\/p>\n
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy\u00ae may affect the way some medicines work and some medicines may affect the way Wegovy\u00ae works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy\u00ae slows stomach emptying and can affect medicines that need to pass through the stomach quickly.<\/p>\n
What are the possible side effects of Wegovy\u00ae?
Wegovy\u00ae may cause serious side effects, including:<\/p>\n
inflammation of your pancreas (pancreatitis). Stop using Wegovy\u00ae and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back<\/p>\n
gallbladder problems. Wegovy\u00ae may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools<\/p>\n
increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy\u00ae. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery<\/p>\n
dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away<\/p>\n
severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy\u00ae. Tell your healthcare provider if you have stomach problems that are severe or will not go away<\/p>\n
serious allergic reactions. Stop using Wegovy\u00ae and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat<\/p>\n
change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy\u00ae <\/p>\n
increased heart rate. Wegovy\u00ae can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes<\/p>\n
food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy\u00ae may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy\u00ae before you are scheduled to have surgery or other procedures<\/p>\n
The most common side effects of Wegovy\u00ae may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss.<\/p>\n
Please click here<\/a> for\u00a0Prescribing Information including Boxed Warning\u00a0and\u00a0Medication Guide\u00a0for Wegovy\u00ae.<\/p>\n About Novo Nordisk Contacts for further information<\/p>\n _______________________<\/p>\n Reference<\/p>\n Novo Nordisk A\/S. Data on file.<\/p>\n \u00a9 2026\u00a0Novo Nordisk All rights\u00a0reserved. US26SEMO01179 June\u00a02026<\/p>\n View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/wegovy-pill-prescriptions-surpass-3-million-1-filled-roughly-every-5-seconds-bringing-glp-1-therapy-to-people-with-obesity-previously-untreated-while-novo-nordisk-unveils-new-data-at-ada-2026-302793337.html<\/a><\/p>\n
Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases \u2014 from diabetes and obesity to rare blood and endocrine disorders \u2014 by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 67,900 people and markets products in roughly 170 countries. In the United States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in seven states plus Washington, D.C. For more information, visit novonordisk.com<\/a> and novonordisk-us.com<\/a>, and follow us on Facebook<\/a>, Instagram<\/a>, X<\/a>, LinkedIn<\/a>, and YouTube<\/a>.<\/p>\n Novo Nordisk, Inc. (PRNewsFoto\/Novo Nordisk)
Cision <\/p>\n